Abstract:AIM:To prepare hybridoma cell lines that secrete monoclonal antibodies against hepatitis C virus (HCV) recombinant proteins NS3 and NS5 and to evaluate their use in the study of HCV NS3 and NS5 antigen distribution in human liver tissue.METHODS:Hybridoma cell lines were generated using spleen cells from BALB/C mice immunized with recombinant NS3 and NS5 proteins, following conventional protocols. Antibody-secreting cells were screened by solid phase ELISA and cloned by limited dilution. The specificity of the monoclonal antibodies was determined by testing hybridoma culture supernatants by Western blots of E. coli expressing the recombinant HCV proteins and ELISA with HCV core and hepatitis B virus (HBV) antigens. The monoclonal antibodies were employed in immunohistochemistry studies to determine the distribution of HCV NS5 and NS3 antigens in 51 paraffin embedded human liver tissue samples.RESULTS:Eight hybridoma cell lines secreting monoclonal antibodies against HCV NS3 and NS5 proteins were generated and named 2B6, 2F3, 3D8, 3D9, 8B2, 6F11, 4C6 and 7D9. Only one of them, 2B6 (secreting antibodies against NS3 protein), cross-reacted with the C7 polypeptide, a different recombinant NS3 polypeptide. The rest of the cell lines showed no cross-reactivity with HCV core or HBV antigens. In addition, monoclonal antibodies against NS3 antigens did not cross-react with NS5 antigens, and vice versa. In immunohistochemistry studies, these monoclonal antibodies did not detect HCV antigens in specimens from patients infected only with HBV (n = 20). In HCV-infected specimens (n = 31), the rates of positive detection of NS3 and NS5 antigens were 51.6% (16/31) and 54.9% (17/31), respectively. Six of these 31 specimens were from patients infected only with HCV and half of them were positive for HCV NS3 and NS5 antigens. In specimens from patients co-infected with HBV and HCV (n = 25), the rates of NS3 and NS5 antigen positive detection were 52% (13/25) and 56% (14/25), respectively, which are similar to those obtained in samples from patients infected only with HCV. In specimens from chronic active cirrhosis patients, the rates of HCV NS3 and NS5 antigen detection were 70.6% (12/17) and 76.5% (13/17), respectively.CONCLUSION:We successfully prepared monoclonal antibodies that are specific against recombinant HCV NS3 and NS5 proteins and could be useful for clinical immunohistochemistry diagnosis.

Preparation and functional evaluation of monoclonal antibodies targeting Hepatitis B Virus Polymerase

Identification and Mapping of HBsAg Loss-Related B-Cell Linear Epitopes in Chronic HBV Patients by Peptide Array

Longitudinal Mapping of Hepatitis B Vaccine-Induced B-cell Linear Epitopes in Healthy Individuals

A Human Monoclonal Antibody Against Small Envelope Protein of Hepatitis B Virus with Potent Neutralization Effect.

Characterization and Clinical Application of a Monoclonal Antibody to Hepatitis B Virus Large Surface Proteins

Development of monoclonal antibodies to target the large surface protein of hepatitis B virus and their use in therapeutic and diagnostic applications

The characterization and structural basis of a human broadly binding antibody to HBV core protein

[Preparation of Monoclonal Antibody Directed Against Hepatitis B Virus X Protein and Detection of Reactive Antigen in Hepatocellular Carcinoma].

Characterization and Engineering of Broadly Reactive Monoclonal Antibody Against Hepatitis B Virus X Protein That Blocks Its Interaction with DDB1.

Identification of novel hepatitis B virus therapeutic vaccine candidates derived from polymerase protein

An Aptamer Targets Hbv Core Protein And Suppresses Hbv Replication In Hepg2.2.15 Cells

A broadly reactive monoclonal antibody detects multiple genotypes of hepatitis B virus X protein

A Combination of Human Broadly Neutralizing Antibodies against Hepatitis B Virus HBsAg with Distinct Epitopes Suppresses Escape Mutations

Prolonged suppression of HBV in mice by a novel antibody that targets a unique epitope on hepatitis B surface antigen

Preparation and Application of Monoclonal Antibodies Against Hepatitis C Virus Nonstructural Proteins.

Selection of HBV preS1 binding penta peptides by phage display

TCR-like bispecific antibodies toward eliminating infected hepatocytes in HBV mouse models

Screening and Evaluation of Novel Compounds against Hepatitis B Virus Polymerase Using Highly Purified Reverse Transcriptase Domain

Novel fully automated prototype assays for specific detection of phosphorylated and non-phosphorylated Hepatitis B core antigens.

HBsAg and TLR7/8 dual-targeting antibody-drug conjugates induce sustained anti-HBV activity in AAV/HBV mice: a preliminary study

Recent Progress on Neutralizing Antibodies against Hepatitis B Virus and its Implications.